Dr Reddys launches Glimy MP1 & Glimy MP2

Dr Reddys Laboratories Ltd has announced that Glimy MP^TM (Glimepiride+ Metformin+ Pioglitazone) has been launched nationwide in July 2007 marking the entry of the Company in the triple drug combination oral hypoglycemic agents market. Glimy MP^TM is an extension of the existing products of the Company, used in the management of Type 2 diabetes. It is a one step approach to intensive glycemic control.

Glimy MP^TM is available in dosages of 1mg (Glimy MP1) and 2mg (Glimy MP2), in sizes of 10tabs / strip and 10 strips / pack. The triple drug combination offers the range of options available for the doctor to address their needs in different situations in the management of Type 2 diabetes.

The stock closed the day at Rs.680.35, up by Rs.4.30 or 0.64%. The stock hit an intraday high of Rs.684.35 and low of Rs.676. The total traded quantity was 96267 compared to 2 week average of 76268.

Source : Equity Bulls

Keywords